Combination of EP₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

References

• Koury J, Lucero M, Cato C, Chang L, Geiger J, Henry D, Hernandez J, Hung F, Kaur P, Teskey G, et al. Immunotherapies: exploiting the immune system for cancer treatment. J Immunol Res. 2018;2018:9585614. doi:10.1155/2018/9585614.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–16. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81.
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi:10.3389/fonc.2018.00086.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21(4):687–692. doi:10.1158/1078-0432.CCR-14-1860.
   PubMed Web of Science ®Google Scholar
• Cassim S, Pouyssegur J. Tumor microenvironment: a metabolic player that shapes the immune response. Int J Mol Sci. 2019;21(1):157. doi: 10.3390/ijms21010157.
   PubMed Web of Science ®Google Scholar
• Iorgulescu JB, Braun D, Oliveira G, Keskin DB, Wu CJ. Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018;10(1):87. doi:10.1186/s13073-018-0598-2.
   PubMed Web of Science ®Google Scholar
• Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–386. doi:10.1093/carcin/bgp014.
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000. doi:10.1161/ATVBAHA.110.207449.
   PubMed Web of Science ®Google Scholar
• Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol. 2013; 35(2):123–137. doi:10.1007/s00281-012-0342-8.
   PubMed Web of Science ®Google Scholar
• Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol. 2012;188(1):21–28. doi:10.4049/jimmunol.1101029.
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107(4):1183–1188. doi:10.1016/0016-5085(94)90246-1.
   PubMed Web of Science ®Google Scholar
• Matsubayashi H, Infante JR, Winter J, Klein AP, Schulick R, Hruban R, Visvanathan K, Goggins M. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6(10):1569–1575. doi:10.4161/cbt.6.10.4711.
   PubMed Web of Science ®Google Scholar
• Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK, Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001;7(4):861–867.
   PubMed Web of Science ®Google Scholar
• Petkova DK, Clelland C, Ronan J, Pang L, Coulson JM, Lewis S, Knox AJ. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir Med. 2004;98(2):164–172. doi:10.1016/j.rmed.2003.09.006.
   PubMed Web of Science ®Google Scholar
• Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90(6):455–460. doi:10.1093/jnci/90.6.455.
   PubMedGoogle Scholar
• Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42(1):73–78. doi:10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G.
   PubMed Web of Science ®Google Scholar
• Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology. 1999;29(3):688–696. doi:10.1002/hep.510290355.
   PubMed Web of Science ®Google Scholar
• Czachorowski MJ, Amaral AF, Montes-Moreno S, Lloreta J, Carrato A, Tardón A, Morente MM, Kogevinas M, Real FX, Malats N; SBC/EPICURO investigators. Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. PLoS One. 2012;7(9):e45025. doi:10.1371/journal.pone.0045025.
   PubMed Web of Science ®Google Scholar
• Rich TA, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas. Am J Clin Oncol. 2003. 26(4):S110–3. doi:10.1097/01.COC.0000074148.37768.3E.
   PubMed Web of Science ®Google Scholar
• Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, Ingersoll C, Parent L, Lee W, Liu D, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology. 2017;6(8):e1338239. doi:10.1080/2162402X.2017.1338239.
   PubMed Web of Science ®Google Scholar
• Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother. 2012;35(2):179–188. doi:10.1097/CJI.0b013e318247a5e9.
   PubMed Web of Science ®Google Scholar
• Sreeramkumar V, Fresno M, Cuesta N. Prostaglandin E2 and T cells: friends or foes? Immunol Cell Biol. 2012. 90(6):579–586. doi:10.1038/icb.2011.75.
   PubMed Web of Science ®Google Scholar
• Ching MM, Reader J, Fulton AM. Eicosanoids in cancer: prostaglandin E2 receptor 4 in cancer therapeutics and immunotherapy. Front Pharmacol. 2020;11:819. doi:10.3389/fphar.2020.00819.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Ishihara S, Sato H, Rumi MA, Kawashima K, Miyaoka Y, Suetsugu H, Kazumori H, Cava CF, Kadowaki Y, et al. Activation of prostaglandin E2-receptor EP2 and EP4 pathways induces growth inhibition in human gastric carcinoma cell lines. J Lab Clin Med. 2002;140(2):92–102. doi:10.1016/S0022-2143(02)00023-9.
   PubMed Web of Science ®Google Scholar
• Mizuno R, Kawada K, Sakai Y. Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci. 2019;20(24):6254. doi: 10.3390/ijms20246254.
   Web of Science ®Google Scholar
• Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs. 2002;13(2):127–137. doi:10.1097/00001813-200202000-00003.
   PubMed Web of Science ®Google Scholar
• Stratton MS, Alberts DS. Current application of selective COX-2 inhibitors in cancer prevention and treatment. Oncology (Williston Park). 2002;16:37–51.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–884. doi:10.1056/NEJMoa061355.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, et al. Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (alliance). J Clin Oncol. 2017; 35(19):2184–2192. doi:10.1200/JCO.2016.71.3743.
   PubMed Web of Science ®Google Scholar
• Huang H, Aladelokun O, Ideta T, Giardina C, Ellis LM, Rosenberg DW, et al. Inhibition of PGE2/EP4 receptor signaling enhances oxaliplatin efficacy in resistant colon cancer cells through modulation of oxidative stress. Sci Rep. 2019;9(1):4954. doi:10.1038/s41598-019-40848-4.
   PubMedGoogle Scholar
• Li B, Li X, Xiong H, Zhou P, Ni Z, Yang T, Zhang Y, Zeng Y, He J, Yang F, et al. Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells. Oncotarget. 2017;8(31):51748–51757. doi:10.18632/oncotarget.18518.
   PubMedGoogle Scholar
• Hutchinson L. Immunotherapy: evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2015;12:622.
   Web of Science ®Google Scholar
• Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, Li W, Wu G, Ren J, Wang Z, et al. Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology. 2016;5(2):e1074374.
   PubMed Web of Science ®Google Scholar
• Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anestesiol. 2005;71:461–470.
   PubMedGoogle Scholar
• Sharma JN, Jawad NM. Adverse effects of COX-2 inhibitors. ScientificWorldJournal. 2005;5:629–645. doi:10.1100/tsw.2005.82.
   PubMed Web of Science ®Google Scholar
• Brænne I, Willenborg C, Tragante V, Kessler T, Zeng L, Reiz B, Kleinecke M, von Ameln S, Willer CJ, Laakso M, et al. A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci Rep. 2017;7(1):10252. doi:10.1038/s41598-017-10928-4.
   PubMedGoogle Scholar
• Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK. EP4 as a therapeutic target for aggressive human breast cancer. Int J Mol Sci. 2018;19(4):1019.
   Web of Science ®Google Scholar
• .Miao J, Lu X, Hu Y, Piao C, Wu X, Liu X, Huang C, Wang Y, Li D, Liu J. Prostaglandin E2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. Oncotarget. 2017;8(52):89802–89810. doi:10.18632/oncotarget.21155.
   PubMedGoogle Scholar
• Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–519. doi:10.1038/s41422-020-0337-2.
   PubMed Web of Science ®Google Scholar
• Hong DS, Parikh A, Shapiro G, Varga A, Naing A, Meric-Bernstam F, Ataman O, Reyderman L, Binder T, Ren M, et al. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer. 2020;8(1.
   Web of Science ®Google Scholar
• Colucci J, Boyd M, Berthelette C, Chiasson JF, Wang Z, Ducharme Y, Friesen R, Wrona M, Levesque JF, Denis D, et al. Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]be nzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. Bioorg Med Chem Lett. 2010;20(12):3760–3763. doi:10.1016/j.bmcl.2010.04.065.
   PubMed Web of Science ®Google Scholar
• PClark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, Therien AG, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbe nzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008;325(2):425–434. doi:10.1124/jpet.107.134510.
   PubMed Web of Science ®Google Scholar
• Burch JD, Belley M, Fortin R, Deschênes D, Girard M, Colucci J, Farand J, Therien AG, Mathieu MC, Denis D, Vigneault E, et al. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor. Bioorg Med Chem Lett. 2008;18(6):2048–2054. doi:10.1016/j.bmcl.2008.01.103.
   PubMed Web of Science ®Google Scholar
• Take Y, Koizumi S, Nagahisa A. Prostaglandin E receptor 4 antagonist in cancer immunotherapy: mechanisms of action. Front Immunol. 2020;11:324. doi:10.3389/fimmu.2020.00324.
   PubMed Web of Science ®Google Scholar
• Liu D, Jenkins RW, Sullivan RJ. Mechanisms of resistance to immune checkpoint blockade. Am J Clin Dermatol. 2019;20(1):41–54. doi:10.1007/s40257-018-0389-y.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001.
   PubMed Web of Science ®Google Scholar
• Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10:655–683.
   PubMed Web of Science ®Google Scholar
• Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53(6):1215–1229. e8. doi:10.1016/j.immuni.2020.10.020.
   PubMed Web of Science ®Google Scholar
• Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, Fulton AM. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology. 2013;2(1):e22647. doi:10.4161/onci.22647.
   PubMed Web of Science ®Google Scholar
• Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23(3):144–150. doi:10.1016/S1471-4906(01)02154-8.
   PubMed Web of Science ®Google Scholar
• Jin Y, Smith C, Hu L, Coutant DE, Whitehurst K, Phipps K, McNearney TA, Yang X, Ackermann B, Pottanat T, et al. LY3127760, a selective prostaglandin E4 (EP4) receptor antagonist, and celecoxib: a comparison of pharmacological profiles. Clin Transl Sci. 2018;11(1):46–53. doi:10.1111/cts.12497.
   PubMed Web of Science ®Google Scholar
• Vassiliou E, Jing H, Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol. 2003;223(2):120–132. doi:10.1016/S0008-8749(03)00158-8.
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S, Rogers NC, Sahai E, Zelenay S, Reis E, Sousa C. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1037. e14. doi:10.1016/j.cell.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–1284. doi:10.1101/gad.314617.118.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002;277(52):50828–50833. doi:10.1074/jbc.M210707200.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang L, Kang D, Yang D, Tang Y. Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8(+) T cells in patients with lung cancer. Oncol Lett. 2018;15(1):552–558. doi:10.3892/ol.2017.7279.
   PubMed Web of Science ®Google Scholar
• Sun X, Li Q. Prostaglandin EP2 receptor: novel therapeutic target for human cancers (Review). Int J Mol Med. 2018;42(3):1203–1214. doi:10.3892/ijmm.2018.3744.
   PubMed Web of Science ®Google Scholar
• Harizi H, Grosset C, Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol. 2003;73(6):756–763. doi:10.1189/jlb.1002483.
   PubMed Web of Science ®Google Scholar
• Huang L, Li Y, Du Y, Zhang Y, Wang X, Ding Y, Yang X, Meng F, Tu J, Luo L, Sun C. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat Commun. 2019;10(1):4871. doi:10.1038/s41467-019-12771-9.
   PubMed Web of Science ®Google Scholar
• Kune GA. Colorectal cancer chemoprevention: aspirin, other NSAID and COX-2 inhibitors. Aust N Z J Surg. 2000;70(6):452–455. doi:10.1046/j.1440-1622.2000.01844.x.
   PubMedGoogle Scholar
• Majumder M, Xin X, Liu L, Girish GV, Lala PK. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Cancer Sci. 2014;105(9):1142–1151. doi:10.1111/cas.12475.
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998. 58(2):362–366.
   PubMed Web of Science ®Google Scholar
• Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel). 2016;8(4):45. doi: 10.3390/cancers8040045.
   Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, et al. STK11/LKB1 mutations and pd-1 inhibitor resistance in kras-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–835. doi:10.1158/2159-8290.CD-18-0099.
   PubMed Web of Science ®Google Scholar
• Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest. 2012;92(8):1115–1128. doi:10.1038/labinvest.2012.90.
   PubMed Web of Science ®Google Scholar
• Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, Postovit LM, Hess D, Lala PK. COX-2 induces breast cancer stem cells via EP4/PI3K/AKT/NOTCH/WNT axis. Stem Cells. 2016;34(9):2290–2305. doi:10.1002/stem.2426.
   PubMed Web of Science ®Google Scholar